Ovarian cancer treatment options, survival rates, and the newest FDA approvals in 2026

Ovarian cancer sits in an uncomfortable paradox that every newly diagnosed woman and her family must confront immediately. It is among the most lethal cancers affecting women, yet it is not among the most common. That combination has historically meant less public awareness, inadequate early-detection infrastructure, and a treatment landscape that moved more slowly than the disease itself. That dynamic is changing at a pace not seen in years. The two months between February and late March 2026 alone produced two separate US Food and Drug Administration approvals for platinum-resistant ovarian cancer, a segment of the patient population that had long been medically underserved. For anyone navigating a new diagnosis, a recurrence, or a decision about which clinical trial to pursue, understanding the current state of ovarian cancer science and clinical care is not background reading. It is a prerequisite.

What is ovarian cancer and which women are most likely to be diagnosed with it?

Ovarian cancer is not a single disease. The term covers a biologically diverse group of malignancies arising from the ovaries, fallopian tubes, and the peritoneum, the tissue lining the abdominal cavity. Globally, ovarian cancer accounts for more than 324,000 new cases and more than 200,000 deaths annually, making it the seventh most common cancer in women and the most lethal of all gynaecological malignancies. Within the United States, approximately 21,010 women are projected to receive a new diagnosis of ovarian cancer in 2026, and around 12,450 women are expected to die from the disease in the same year. The condition develops predominantly in older women, with around half of all diagnoses occurring in women aged 63 or above.

The overall incidence of epithelial ovarian tumours is in the range of nine to seventeen per 100,000 women, with the highest rates observed in high-income countries. Incidence rises with age, with the largest number of patients found in the 60 to 64 age group. In lower-income countries, the median age at diagnosis is approximately a decade earlier. The disease is more common among White women than Black women in the United States, though disparities in access to care mean outcomes differ sharply by geography, insurance status, and ethnicity. The good news embedded in the statistics is directional: ovarian cancer incidence has declined over the past several decades, likely owing in part to wider use of oral contraceptives and reduced use of menopausal hormone therapy. Death rates are also falling, though improved treatment is the more significant driver of that trend.

How is ovarian cancer classified and staged, and why does the subtype matter for treatment?

The most common subtype by a considerable margin is high-grade serous carcinoma, which accounts for the largest share of both diagnoses and deaths. About 90 percent of ovarian cancers involve epithelial tumours, while stromal tumours represent around five percent of cases and germ cell tumours are significantly rarer. Recent research has revised longstanding assumptions about where high-grade serous cancers originate. Evidence now suggests it frequently originates from the fallopian tube, with serous tubal intraepithelial carcinoma as a possible precursor lesion, rather than from the ovarian surface epithelium as previously believed. Low-grade serous ovarian cancer is a distinct and rarer entity that behaves differently from the high-grade form and had historically lacked dedicated approved therapies until 2025.

Staging follows the International Federation of Gynecology and Obstetrics system and determines both treatment planning and prognosis. Stage one disease is confined to the ovaries or fallopian tubes. Stage two involves spread within the pelvis. Stage three, the most common presentation at diagnosis, involves spread to the abdominal lining or regional lymph nodes. Stage four involves distant metastasis to organs such as the liver or the interior of the lung. The staging determination is primarily surgical, and operative findings determine the precise histologic diagnosis, stage, and prognosis of the patient.

Why is ovarian cancer so hard to detect early, and what warning signs should women know about?

The central clinical tragedy of ovarian cancer is the gap between when the disease begins and when it causes symptoms perceptible enough to prompt a medical visit. Ovarian cancer is hard to find early because it often does not cause symptoms until the cancer is advanced. Even regular pelvic exams usually cannot detect small tumours in the ovaries. Unlike some other cancers, there is no screening test that works well enough to find ovarian cancer early in the general population.

The symptoms, when they do emerge, are non-specific enough to overlap with common gastrointestinal and urinary conditions. Women should be especially mindful of abdominal bloating, pelvic pain, and changes in bowel habits, and should promptly speak with a physician if these changes persist. Feeling full very quickly after eating small amounts and urinary urgency or frequency are also among the most commonly reported signals. Prompt attention to these symptoms may improve the odds of early diagnosis and successful treatment. Importantly, a Pap smear, which many women associate with gynaecological health screening, tests only for cervical abnormalities. It has no diagnostic value for ovarian cancer.

The absence of an effective population-wide screening test is a structural problem that researchers have been working to address for decades. The CA-125 blood test and transvaginal ultrasound are the two most studied tools, but neither is sufficiently sensitive or specific when used alone for general population screening. The UK Collaborative Trial of Ovarian Cancer Screening explored a multimodal approach combining CA-125 and transvaginal ultrasound, and its long-term data found that women in the multimodal screening group had a lower incidence of advanced-stage disease at diagnosis, a higher likelihood of undergoing primary surgery, and were more likely to have no residual disease after debulking surgery. These findings are encouraging but have not yet translated into a confirmed mortality benefit sufficient to justify universal screening programmes.

What does the survival rate for ovarian cancer look like at each stage of diagnosis?

Staging at diagnosis is the single most powerful predictor of outcome. Ovarian cancer confined to the ovaries at stage one can be cured in up to 90 percent of patients, and disease confined to the pelvis at stage two is associated with a five-year survival of around 70 percent. Disease that has spread beyond the pelvis at stages three and four carries a long-term survival rate of 20 percent or less. The problem that makes these numbers so challenging in practice is that the majority of women are not diagnosed at stage one or two.

Only around 20 percent of ovarian cancer cases are diagnosed at the local stage. The five-year relative survival for localised ovarian cancer is approximately 91.7 percent. For the majority who receive a diagnosis after the cancer has spread, outcomes depend heavily on tumour biology, fitness for surgery, response to platinum-based chemotherapy, and access to emerging treatments. Fewer women are dying of ovarian cancer overall, a trend attributable to better treatments and a declining rate of new diagnoses. The trajectory is cautiously positive, but the pace of progress must accelerate given how many women are still presenting at advanced stages.

Who should consider BRCA genetic testing and what does a positive result mean for ovarian cancer risk?

Genetic predisposition accounts for a meaningful proportion of ovarian cancer cases, and understanding individual risk has both preventive and therapeutic implications. Mutations in the BRCA1 and BRCA2 genes are the most clinically significant inherited risk factors. Women carrying a BRCA1 pathogenic mutation face a substantially elevated lifetime risk of ovarian cancer compared to the general population, and the same applies to BRCA2 mutation carriers, though with a different risk profile and age of onset.

Guidelines suggest that women with a pathogenic BRCA1 mutation consider risk-reducing bilateral salpingo-oophorectomy between the ages of 35 and 40, and women with a BRCA2 pathogenic mutation between the ages of 40 and 45. Surgical removal of both ovaries and fallopian tubes reduces risk substantially and is associated with a reduction in ovarian cancer-specific mortality. The decision to undergo risk-reducing surgery is complex, particularly for younger women who may not have completed their families, and requires detailed discussion with specialist gynaecologic oncologists. Genetic testing is now strongly recommended not only for women diagnosed with ovarian cancer but increasingly for their first-degree relatives. A mutation finding in a patient opens the door to cascade testing across a family and can change surveillance protocols and surgical timing for other women in that family.

Beyond BRCA, homologous recombination deficiency testing has emerged as a broader category that identifies tumour-level DNA repair defects predictive of response to PARP inhibitors, even in patients without inherited BRCA mutations. Recent progress in precision oncology has expanded therapeutic options well beyond the BRCA era, with novel biomarker-driven approaches continuing to refine how patients are selected for specific treatments.

How is ovarian cancer treated, and what has changed most significantly since 2023?

Primary treatment for most ovarian cancer presentations combines cytoreductive surgery, also called debulking, with platinum-based chemotherapy. The goal of debulking surgery is to remove as much tumour mass as possible, as residual disease volume strongly correlates with chemotherapy response and survival. For patients with advanced-stage disease who are not immediately fit for surgery, neoadjuvant chemotherapy before planned surgery is appropriate in selected cases, with histological confirmation of diagnosis considered essential before starting.

Carboplatin and paclitaxel have been the backbone of first-line chemotherapy for decades. PARP inhibitors emerged as a major maintenance therapy advance through the late 2010s and early 2020s, extending progression-free survival substantially for eligible patients after completion of primary treatment. However, the use of PARP inhibitors has since been narrowed, with their indication now aligned more specifically with genomic alterations in the tumour, either germline or somatic BRCA mutations or homologous recombination deficiency. Patients who do not carry those alterations are now being directed toward different classes of drug combinations.

For recurrent ovarian cancer, the treatment landscape bifurcates sharply between platinum-sensitive and platinum-resistant disease. Platinum-sensitive recurrence, defined as relapse more than six months after completing platinum chemotherapy, allows re-treatment with platinum-based regimens. Platinum-resistant recurrence, where the cancer progresses during or within six months of platinum treatment, has historically been associated with very poor outcomes and limited effective options. That picture changed markedly between 2025 and early 2026.

What are the newest FDA-approved ovarian cancer drugs and how do they work for resistant disease?

The two most significant regulatory milestones in ovarian cancer in the twelve months leading to April 2026 both addressed the platinum-resistant setting. The first was the approval in May 2025 of a targeted combination for a rare but distinct patient population. The FDA granted accelerated approval to avutometinib plus defactinib for adult patients with KRAS-mutated recurrent low-grade serous ovarian cancer after at least one prior systemic therapy, marking the first-ever FDA-approved treatment specifically for low-grade serous ovarian cancer. The approval was grounded in data from the phase two RAMP-201 trial, which demonstrated a confirmed overall response rate of 44 percent in patients with KRAS mutations and a median progression-free survival of approximately 22 months. This was a landmark moment for a patient population that had been largely excluded from prior treatment advances.

The second major regulatory event came in March 2026. On March 25, 2026, the FDA approved relacorilant, branded Lifyorli and developed by Corcept Therapeutics, in combination with nab-paclitaxel for adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens, at least one of which included bevacizumab. The approval was based on the phase three ROSELLA trial, which enrolled 381 patients. The combination achieved a 35 percent reduction in mortality risk and a 4.1-month improvement in median overall survival versus nab-paclitaxel alone, alongside a 30 percent reduction in the risk of disease progression. Crucially, the regimen is biomarker-agnostic, meaning patients do not require specific genetic testing to be eligible.

The biomarker-agnostic designation matters considerably for access. One of the recurring frustrations in ovarian cancer treatment has been that the most effective newer agents were restricted to patients whose tumours carried specific molecular markers, leaving a substantial portion of the patient population without those advances. Lifyorli’s approval removed that barrier for the platinum-resistant population meeting the eligibility criteria. The FDA had also approved pembrolizumab with weekly paclitaxel, with or without bevacizumab, for platinum-resistant ovarian cancer shortly before, but that combination is limited to patients with PD-L1-positive tumours, whereas Lifyorli with nab-paclitaxel requires no biomarker testing.

The wave behind these approvals points to a broader shift in the treatment paradigm. Antibody-drug conjugates are attracting increasing investment and clinical attention. Mirvetuximab soravtansine, the first ADC evaluated in ovarian cancer, presented final overall survival data from the phase three MIRASOL trial at the Society of Gynecologic Oncology 2025 meeting, confirming a sustained progression-free survival benefit over investigator-choice chemotherapy in patients with high folate receptor alpha-expressing platinum-resistant high-grade serous ovarian cancer, alongside a statistically significant overall survival advantage.

How does ovarian cancer treatment compare to other gynaecological cancers and what are the research priorities?

Ovarian cancer occupies a distinct position within gynaecological oncology relative to cervical and endometrial cancer. Cervical cancer, driven largely by human papillomavirus, has benefited from a vaccine and well-established population-wide screening. Endometrial cancer, while more common than ovarian cancer, is more frequently diagnosed at an early and potentially curable stage because abnormal uterine bleeding typically presents before the cancer has spread widely. Ovarian cancer lacks both a reliable screening test and a symptomatic early-warning signal equivalent to abnormal bleeding. That structural disadvantage means that even within the speciality of gynaecologic oncology, ovarian cancer generates disproportionate research intensity relative to incidence because its mortality burden is so high.

The competitive landscape within ovarian cancer treatment itself has grown considerably more complex. Where PARP inhibitors once dominated the post-primary-treatment conversation, the field is now navigating a multiclass environment that includes PARP inhibitors for genomically selected patients, ADCs for specific biomarker-positive populations, immune checkpoint inhibitors for patients with particular tumour characteristics, and targeted combinations for genetically defined subtypes such as the KRAS-mutated low-grade serous population. The challenge for clinicians and patients is sequencing these options appropriately and understanding which trials may apply when standard options are exhausted.

A brief history of ovarian cancer research, advocacy, and the funding that shaped treatment progress

Ovarian cancer advocacy gained significant momentum through the 1990s following the identification of BRCA1 and BRCA2 as major inherited risk genes, discoveries that both galvanised research funding and created actionable pathways for high-risk women. The Ovarian Cancer Research Alliance, founded in 1998 through a merger of earlier advocacy organisations, became the largest non-governmental funder of ovarian cancer research in the United States and has remained an influential voice in policy and patient access. The National Comprehensive Cancer Network has maintained ovarian cancer treatment guidelines, with the most recent evidence-based update incorporating the regulatory changes of early 2026. The broader institutional framework supporting ovarian cancer research spans the National Cancer Institute’s SEER programme, multiple cooperative oncology groups including the Gynecologic Oncology Group, and a network of NCI-designated comprehensive cancer centres with specialist gynaecologic oncology programmes.

What early detection tools are researchers developing to catch ovarian cancer before it spreads?

The search for an effective early detection strategy remains one of the most consequential open questions in cancer medicine. Several parallel approaches are advancing. Liquid biopsy, which analyses circulating tumour DNA from a blood sample, is under investigation across multiple studies for both early detection and treatment monitoring. Researchers at the AACR Annual Meeting 2025 showed that blood-based levels of a specific microRNA, miR-203a, were especially elevated in aggressive ovarian cancers and could predict chemotherapy resistance, pointing to its potential as both an early warning signal and a new therapeutic target.

Imaging innovation is also part of the early detection push. A study presented at the AACR Annual Meeting 2025 showcased a specialised imaging system called OVASEEK that identified early disease changes in fallopian tubes that standard tests missed in approximately one in five samples. The relevance of fallopian tube imaging is directly connected to the updated understanding of high-grade serous carcinoma’s origins, which positions the distal fallopian tube as the likely site of earliest disease.

Spatial transcriptomics, which maps gene expression patterns within intact tissue samples while preserving the precise location of each cell, is opening new windows into the biology of chemotherapy resistance. Advances in this technology revealed significant multidrug resistance properties in several persistent cancer cell populations across more than 320 epithelial ovarian cancer patients, while also identifying sensitivity to alternate FDA-approved drug classes, suggesting that existing drugs could be deployed more effectively by matching them to specific cell populations. Novel biomarkers including HE4, mesothelin, and osteopontin are being studied alongside CA-125 to improve the specificity of diagnostic panels.

What is the outlook for ovarian cancer patients and the treatment pipeline through 2027 and beyond?

The trajectory through 2027 and 2028 is shaped by several converging forces. The ADC pipeline is the most closely watched development in the field. Multiple phase three trials are testing ADCs in different lines of therapy and in different biomarker-defined patient populations, and results from several of those trials are expected in the near term. ADCs are positioned to reshape the ovarian cancer treatment landscape in a manner comparable to what PARP inhibitors achieved in their era, though with applicability across a broader range of tumour subtypes.

The regulatory environment is also becoming more favourable for innovation following the ROSELLA and KEYNOTE-B96 data. These two trials, both addressing platinum-resistant ovarian cancer, are expected to influence regulatory strategies for the next generation of drugs by establishing weekly paclitaxel as a more rigorous comparator standard in trial design. That shift has practical consequences for how quickly and reliably future drugs can be evaluated and approved.

Early detection research is approaching a stage where multimodal approaches combining liquid biopsy, advanced imaging, and multi-marker panels may begin to reach clinical validation, though widespread population-level deployment remains some years away. Genetic testing access continues to expand as costs fall and clinical guidelines increasingly recommend testing not just for patients but for at-risk family members. The net effect, if these trends continue, is a gradual but meaningful shift in the proportion of women diagnosed before their disease has spread, which would represent the most durable long-term improvement in mortality.

For patients navigating treatment decisions today, the core message from the current evidence base is that ovarian cancer care has become substantially more complex and substantially more promising than it was even three years ago. Specialist gynaecologic oncology centres, access to genomic tumour profiling, and awareness of open clinical trials are the practical levers most likely to improve individual outcomes at every stage of the disease.

What are the most important facts about ovarian cancer that every patient and caregiver should know before their next appointment?

• Ovarian cancer is projected to affect around 21,010 women in the United States in 2026, with death rates declining year on year due to improved treatment.
• More than 75 percent of ovarian cancers are diagnosed after the disease has spread beyond the ovaries, making stage three and four the most common presentations.
• Five-year survival at localised stage one exceeds 90 percent, falling to below 30 percent for advanced metastatic disease, underscoring how critically stage at diagnosis shapes outcome.
• There is no validated population-wide screening test for ovarian cancer; multimodal approaches combining CA-125 and transvaginal ultrasound are the most studied but have not yet produced a confirmed survival benefit in randomised trials.
• In May 2025, the FDA approved the first-ever treatment specifically for KRAS-mutated low-grade serous ovarian cancer, avutometinib plus defactinib, based on a 44 percent response rate in eligible patients.
• In March 2026, the FDA approved Lifyorli (relacorilant) plus nab-paclitaxel for platinum-resistant ovarian cancer, a biomarker-agnostic approval that extends access to patients regardless of molecular profile.
• Antibody-drug conjugates represent the most actively watched pipeline class, with multiple phase three trials underway expected to read out in the next one to two years.
• BRCA1 and BRCA2 genetic testing is now recommended not only for patients but for at-risk family members, with risk-reducing surgery guidelines linked to specific mutation type and age.
• Emerging early detection tools including miRNA blood tests, liquid biopsy, and fallopian tube imaging are advancing toward clinical validation but are not yet standard of care.
• Specialist gynaecologic oncology care, genomic profiling, and active engagement with clinical trial registries remain the highest-impact practical actions for patients at every disease stage.